Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of New Brunswick

$25,000.00

Development of new adsorbent for selective removal of halogenated anesthetics

EF 2011-12

Résumé
The company involved in this project, Blue-Zone Technologies from Toronto, has developed a process based on proprietary granulated adsorbent Deltazite? for selective removal and recovery of low concentration halogenated anesthetics coming from hospital operating rooms. During operation only a small amount of the administered anesthetic, i.e., less than 5% is metabolized by the patient. The remaining 95% either escapes or is vented through hospital ventilation systems unabated directly into the atmosphere. These vapors are considered aggressive greenhouse gases with the Global Warming Potential (GWP) up to 3,766 times higher than for the CO2 and have a 20 year impact. Since these anesthetics are valuable commodities (costing up to $1,200 per liter) the Deltasorb? adsorbent, with captured anesthetics, is regenerated by thermal desorption and then adsorbates liquefied into halogenated condensate. The liquefied condensate is a mix of all three anesthetics and is used as a feedstock for the next process, e.g., Blue-Zone proprietary fractional distillation process, where each component is isolated, separated and purified to meet or exceed the USP anesthetic drug medical standards. Even though the Blue-Zone process has been successfully applied in a number of hospitals in Canada (mainly Toronto area) and USA, the company would like to improve the process and make it more marketable throughout North America and possibly globally. To accomplish this, a new process is essential to be developed by focusing on the development of new adsorbent material. This material should have better selectivity and adsorption capacity in the presence of water vapor, which is a part of the scavanged gas coming from operating rooms, in comparison to the current Deltasorb adsorbent. The company plans to develop the new material in collaboration with the researech group from University of New Brunswick, led by Dr. Mladen Eic. Dr.Eic's group has 25 years of research experience in the area of adsorption in nanoporous materials, from synthesis and characterization to process design and industrial
Programme
Engage Grants Program
Emplacement
New Brunswick, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
419350-2011
Name nom
Eic, Mladen
Department département
Chemical Engineering
Organization id
75
Institution établissement
University of New Brunswick
Province en
New Brunswick
Province fr
Nouveau-Brunswick
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
602
Area of application group en
Construction, urban and rural planning
Area of application group fr
Construction, urbanisme et aménagement rural
Area of application en
Materials performance
Area of application fr
Performance des matériaux
Research subject code
1806
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Separation processes
Research subject fr
Procédés de séparation
Partie
1
Nb partie
1
Application title
Development of new adsorbent for selective removal of halogenated anesthetics
Keyword
NSERC
Application summary
The company involved in this project, Blue-Zone Technologies from Toronto, has developed a process based on proprietary granulated adsorbent Deltazite? for selective removal and recovery of low concentration halogenated anesthetics coming from hospital operating rooms. During operation only a small amount of the administered anesthetic, i.e., less than 5% is metabolized by the patient. The remaining 95% either escapes or is vented through hospital ventilation systems unabated directly into the atmosphere. These vapors are considered aggressive greenhouse gases with the Global Warming Potential (GWP) up to 3,766 times higher than for the CO2 and have a 20 year impact. Since these anesthetics are valuable commodities (costing up to $1,200 per liter) the Deltasorb? adsorbent, with captured anesthetics, is regenerated by thermal desorption and then adsorbates liquefied into halogenated condensate. The liquefied condensate is a mix of all three anesthetics and is used as a feedstock for the next process, e.g., Blue-Zone proprietary fractional distillation process, where each component is isolated, separated and purified to meet or exceed the USP anesthetic drug medical standards. Even though the Blue-Zone process has been successfully applied in a number of hospitals in Canada (mainly Toronto area) and USA, the company would like to improve the process and make it more marketable throughout North America and possibly globally. To accomplish this, a new process is essential to be developed by focusing on the development of new adsorbent material. This material should have better selectivity and adsorption capacity in the presence of water vapor, which is a part of the scavanged gas coming from operating rooms, in comparison to the current Deltasorb adsorbent. The company plans to develop the new material in collaboration with the researech group from University of New Brunswick, led by Dr. Mladen Eic. Dr.Eic's group has 25 years of research experience in the area of adsorption in nanoporous materials, from synthesis and characterization to process design and industrial